Figure_7.tif (373.87 kB)
Download file

Combinational effects of molecular subtype specific drugs with TMZ on patient-derived GBM cells.

Download (0 kB)
figure
posted on 01.08.2014, 03:00 by Young Taek Oh, Hee Jin Cho, Jinkuk Kim, Ji-Hyun Lee, Kyoohyoung Rho, Yun-Jee Seo, Yeon-Sook Choi, Hye Jin Jung, Hyeon Suk Song, Doo-Sik Kong, Ho Jun Seol, Jung-Il Lee, Yeup Yoon, Sunghoon Kim, Do-Hyun Nam, Kyeung Min Joo

(A) The inhibition effect of molecular subtype-specific drugs on the in vitro clonogenicity of matched-subtype patient-derived GBM cells was determined by limiting dilution assay in 13 patient-derived GBM cells. When the ratio of GBM cells with in vitro sphere-forming capacity was significantly reduced in in vitro limiting dilution test (Chi-Square test) compared with control group (DMSO only), the treatment was considered as “effective” [Left, **, Y = Yes (p<0.05), N = No (p>0.05)]. The two representative graphs of which has a significant effect (099T) and has no effect (464T) (Right). The experiments were triplicated and one of them was illustrated. P = Proneural specific treatment, N = Neural specific treatment, C = Classical specific treatment, M = Mesenchymal specific treatment. (B) MGMT methylation status of the 8 patient-derived cells is represented. ***, M = Methylated, UM = Unmethylated. The effects of combinational drug treatment (molecular subtype-specific drugs+TMZ) were determined by limiting dilution assay. When the ratio of GBM cells with in vitro sphere-forming capacity was significantly reduced in in vitro limiting dilution test (Chi-Square test) compared with control group (DMSO only) or TMZ treated group, the treatment was considered as “effective” [**, Y = Yes (p<0.05), N = No (p>0.05)]. The experiments were triplicated and one of them was illustrated.

History